Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6055 in Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT07476066Phase 2Not yet recruiting
- Sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of SYS6055 in aggressive B-cell lymphoma, sponsored by Beijing Kangchuanglian Biopharmaceutical Technology Research. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SYS6055
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT07476066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476066.